Literature DB >> 28245785

Vascular Consequences of Aldosterone Excess and Mineralocorticoid Receptor Antagonism.

Sophocles Chrissobolis1.   

Abstract

Aldosterone binds to mineralocorticoid receptors (MRs) on renal epithelial cells to regulate sodium and water reabsorption, and therefore blood pressure. Recently, the actions of aldosterone outside the kidney have been extensively investigated, with numerous reports of aldosterone having detrimental actions, including in the vasculature. Notably, elevated aldosterone levels are an independent cardiovascular risk factor, and in addition to causing an increase in blood pressure, aldosterone can have blood pressure-dependent and -independent effects commonly manifested in the vasculature in cardiovascular diseases, including oxidative stress, endothelial dysfunction, inflammation, remodeling, stiffening, and plaque formation. Receptor-dependent mechanisms mediating these actions include the MR expressed on vascular endothelial and smooth muscle cells, but also include the angiotensin II type 1 receptor, epidermal growth factor receptor and vascular endothelial growth factor receptor 1, with downstream mechanisms including NADPH oxidase, cyclooxygenase, glucose-6-phosphate dehydrogenase, poly-(ADP ribose) polymerase and placental growth factor. The beneficial actions of MR antagonism in experimental hypertension include improved endothelial function, reduced hypertrophy and remodeling, and in atherosclerosis beneficial actions include reduced plaque area, inflammation, oxidative stress and endothelial dysfunction. Aldosterone excess is detrimental and MR antagonism is beneficial in humans also. The emerging concept of the contribution of aldosterone/MR-induced immunity to vascular pathology will also be discussed. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Aldosterone; endothelial dysfunction; inflammation; mineralocorticoid receptor; oxidative stress; remodeling; vasculature

Mesh:

Substances:

Year:  2017        PMID: 28245785     DOI: 10.2174/1573402113666170228151402

Source DB:  PubMed          Journal:  Curr Hypertens Rev        ISSN: 1573-4021


  9 in total

1.  Mineralocorticoid Receptor Antagonists Decrease the Rates of Positive Screening for Primary Aldosteronism.

Authors:  Yuta Tezuka; Adina F Turcu
Journal:  Endocr Pract       Date:  2020-12       Impact factor: 3.443

Review 2.  Primary Aldosteronism and Ischemic Heart Disease.

Authors:  Shivaraj Patil; Chaitanya Rojulpote; Aman Amanullah
Journal:  Front Cardiovasc Med       Date:  2022-05-23

Review 3.  Vascular Mineralocorticoid Receptor: Evolutionary Mediator of Wound Healing Turned Harmful by Our Modern Lifestyle.

Authors:  Lauren A Biwer; Mary C Wallingford; Iris Z Jaffe
Journal:  Am J Hypertens       Date:  2019-01-15       Impact factor: 2.689

Review 4.  Non-coding RNAs and the mineralocorticoid receptor in the kidney.

Authors:  Michael B Butterworth
Journal:  Mol Cell Endocrinol       Date:  2020-12-07       Impact factor: 4.102

Review 5.  Differential influences of dietary sodium on blood pressure regulation based on race and sex.

Authors:  Austin T Robinson; Megan M Wenner; Nisha Charkoudian
Journal:  Auton Neurosci       Date:  2021-09-04       Impact factor: 2.355

6.  Epithelial Sodium Channel-α Mediates the Protective Effect of the TNF-Derived TIP Peptide in Pneumolysin-Induced Endothelial Barrier Dysfunction.

Authors:  Istvan Czikora; Abdel A Alli; Supriya Sridhar; Michael A Matthay; Helena Pillich; Martina Hudel; Besim Berisha; Boris Gorshkov; Maritza J Romero; Joyce Gonzales; Guangyu Wu; Yuqing Huo; Yunchao Su; Alexander D Verin; David Fulton; Trinad Chakraborty; Douglas C Eaton; Rudolf Lucas
Journal:  Front Immunol       Date:  2017-07-21       Impact factor: 7.561

7.  Comparison of biomarkers of endothelial dysfunction and microvascular endothelial function in patients with primary aldosteronism and essential hypertension.

Authors:  Miaomiao Sang; Yu Fu; Chenmin Wei; Jing Yang; Xueting Qiu; Jingqing Ma; Chao Qin; Feiyan Wu; Xueling Zhou; Tao Yang; Min Sun
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2021 Jan-Dec       Impact factor: 1.636

Review 8.  Is primary aldosteronism a potential risk factor for aortic dissection? A case report and literature review.

Authors:  Ying Zhang; Fang Luo; Peng Fan; Xu Meng; Kunqi Yang; Xianliang Zhou
Journal:  BMC Endocr Disord       Date:  2020-07-31       Impact factor: 2.763

9.  Huoxue Jiedu Huayu Formula Alleviates Cell Pyroptosis in Contralateral Kidneys of 6-Month-Old UUO Rats through the NLRP3/Caspase-1/IL-1β Pathway.

Authors:  Xuelian Ma; Panpan Qiang; Gege Chen; Zheng Wang; Xiangting Wang; Qingyou Xu
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-12       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.